Affordable Access

Publisher Website

Can PPARγ agonists have a role in the management of obesity-related hypertension?

Authors
Journal
Vascular Pharmacology
1537-1891
Publisher
Elsevier
Publication Date
Volume
45
Issue
1
Identifiers
DOI: 10.1016/j.vph.2005.11.010
Keywords
  • Pparγ
  • Peroxisome Proliferator-Activated Receptor
  • Hypertension
  • Obesity
Disciplines
  • Biology

Abstract

Abstract Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. PPARγ is the most extensively studied amongst the three subtypes (α, δ and γ). This receptor is a key modulator of lipid and glucose homeostasis and is predominantly expressed in adipose tissue. Expression of PPARγ is also found in non-adipose tissues including heart, kidney, spleen, and interestingly, in all relevant components of the vasculature: endothelial and smooth muscle cells. These receptors may therefore also play a role in the regulation of vascular tone and blood pressure. Genetic variants of PPARγ have also been associated with features of the metabolic syndrome, including obesity and increased blood pressure. The discovery of synthetic ligands for PPARγ, the Thiazolidinediones (TZDs) has greatly enhanced our understanding of their ligand dependent activation and more importantly their role in vascular pathobiology. Approximately 10 years ago, serendipitous animal experiments demonstrated that despite causing sodium retention, the TZDs actually lowered blood pressure. This review will highlight the role of TZDs in various models of hypertension and discuss their potential role in the management of obesity-related hypertension.

There are no comments yet on this publication. Be the first to share your thoughts.